Biotech Values

[dav1234]

Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment Telintra, with a preliminary agreement reached regarding the design of a Phase 3 trials. In order to focus its resources on the registration program, Telik has decided to stop further enrollment in its ongoing Phase 2 exploratory trials

http://seekingalpha.com/news-article/5370081-telik-announces-preliminary-agreement-on-design-of-phase-3-registration-trial-of-telintra-in-low-to-intermediate-1-risk-myelodysplastic-syndrome